FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
作者信息
Rahman Ahmadur
出版信息
Lancet Oncol. 2014 Dec;15(13):e590. doi: 10.1016/S1470-2045(14)71112-X. Epub 2014 Oct 31.
Abstract
摘要
相似文献
1
FOLFOXIRI and bevacizumab in metastatic colorectal cancer.FOLFOXIRI方案联合贝伐单抗治疗转移性结直肠癌
Lancet Oncol. 2014 Dec;15(13):e590. doi: 10.1016/S1470-2045(14)71112-X. Epub 2014 Oct 31.
2
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?FOLFOXIRI联合贝伐单抗应成为转移性结直肠癌的标准一线治疗方案吗？
Oncologist. 2015 Mar;20(3):236-8. doi: 10.1634/theoncologist.2014-0495. Epub 2015 Feb 6.
3
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.转移性结直肠癌的 FOLFOXIRI 和贝伐珠单抗初始治疗。
N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
4
Cetuximab or bevacizumab in metastatic colorectal cancer?西妥昔单抗或贝伐单抗用于转移性结直肠癌？
Lancet Oncol. 2014 Sep;15(10):1040-1. doi: 10.1016/S1470-2045(14)70360-2. Epub 2014 Jul 31.
5
[Advances in the treatment of metastatic colorectal cancer with bevacizumab].[贝伐单抗治疗转移性结直肠癌的进展]
Tumori. 2006 Sep-Oct;92(5):suppl 1-12.
6
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].[FOLFOXIRI化疗用于转移性结直肠癌一线治疗的综述]
Nihon Rinsho. 2011 Apr;69 Suppl 3:439-45.
7
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.三联化疗（FOLFOXIRI）联合贝伐单抗与双联化疗（FOLFOX/FOLFIRI）联合贝伐单抗用于转移性结直肠癌转化治疗的Meta分析
Cell Physiol Biochem. 2018;48(5):1870-1881. doi: 10.1159/000492508. Epub 2018 Aug 9.
8
Maintenance therapy for metastatic colorectal cancer.转移性结直肠癌的维持治疗
Lancet Oncol. 2015 Oct;16(13):1281-2. doi: 10.1016/S1470-2045(15)00125-4. Epub 2015 Sep 8.
9
Maintenance treatment in metastatic colorectal cancer.转移性结直肠癌的维持治疗。
Lancet Oncol. 2015 Dec;16(16):e582-3. doi: 10.1016/S1470-2045(15)00374-5.
10
Maintenance treatment in metastatic colorectal cancer.转移性结直肠癌的维持治疗。
Lancet Oncol. 2015 Dec;16(16):e583-4. doi: 10.1016/S1470-2045(15)00448-9.
引用本文的文献
1
Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.西妥昔单抗对比贝伐珠单抗维持治疗用于既往接受 8 周期改良 FOLFOXIRI 加西妥昔单抗治疗的亚洲绝经后 KRAS 和 BRAF 野生型转移性结直肠癌患者。
J Int Med Res. 2020 Sep;48(9):300060520930440. doi: 10.1177/0300060520930440.
Zotero 插件